A Look At Insider Reactions To Axsome Therapeutics Inc. (AXSM)

As of Thursday close, Axsome Therapeutics Inc.’s (NASDAQ:AXSM) stock was down -$0.45, moving down -1.74 percent to $25.34. The average number of shares traded per day over the past five days has been 1,423,100 shares. 1 time new highs have been achieved over the past 5 days, with a -$11.40 fall in that time frame. In the last twenty days, the average volume was 1,792,830, while in the previous 50 days, it was 1,157,324.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, AXSM stock retreated -33.92%. Shares of the company fell to $24.13 on 05/12/22, the lowest level in the past month. A 52-week high of $74.10 was reached on 04/05/22 after having rallying from a 52-week low of $19.38. Since the beginning of this year, AXSM’s stock price has dropped by -32.93% or -$12.44, and marked a new high 8 times. However, the stock has declined by -65.80% since its 52-week high.

Axsome Therapeutics Inc. (AXSM) last reported insider trading activity 175 days ago on Nov 19. JEFFS ROGER, the Director of the company, purchased of 3,950 shares for $37.30 on Nov 19. It resulted in a $147,350 investment by the insider. Pizzie Nick added 428 shares at an average price of $34.97 on Nov 18. The insider now owns 201 shares following the transaction. On Nov 18, CHIEF FINANCIAL OFFICER Pizzie Nick bought 527 shares at $35.50 apiece. The transaction was valued at $18,708.

Financial Health

In the three months ended September 29, Axsome Therapeutics Inc.’s quick ratio stood at 3.50, while its current ratio was 3.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 3.35. Based on annual data, AXSM earned $5.7 million in gross profit and brought in $124.71 million in revenue.

In Axsome Therapeutics Inc.’s quarter-end financial report for September 29, it reported total debt of $49.31 million. While analysts expected Axsome Therapeutics Inc. to report -$0.95 quarterly earnings, the actual figure was -$0.93 per share, beating the consensus estimate by 2.10%. The liabilities of Axsome Therapeutics Inc. were 73.86 million at the end of its most recent quarter ended September 29, and its total debt was $50.05 million. The value of shareholders’ equity is $38.91 million.

Technical Picture

This quick technical analysis looks at Axsome Therapeutics Inc.’s (AXSM) price momentum. With a historical volatility rate of 155.83%, the RSI 9-day stood at 33.29% on 12 May.

With respect to its five-day moving average, the current Axsome Therapeutics Inc. price is down by -31.03% percent or -$11.40. At present, AXSM shares trade -33.32% below its 20-day simple moving average and -28.22% percent below its 100-day simple moving average. However, the stock is currently trading approximately -19.43% below its SMA50 and -52.02% below its SMA200.

Stochastic coefficient K was 8.26% and Stochastic coefficient D was 7.26%, while ATR was 3.59. Given the Stochastic reading of 8.25% for the 14-day period, the RSI (14) reading has been calculated as 37.02%. As of today, the MACD Oscillator reading stands at -4.55, while the 14-day reading stands at -4.40.

Analyst Ratings

Axsome Therapeutics Inc. downgraded its rating on Axsome Therapeutics Inc. (NASDAQ: AXSM) to an Equal-weight in a note to investors on August 10, 2021. The analysts firm previously had an Overweight rating on the stock.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles